Wondering How Lupus Is Treated in 2025? Discover the UAE’s Breakthroughs and Proven Care Strategies

In 2025, the United Arab Emirates (UAE) continues to advance systemic lupus erythematosus (SLE) treatment by introducing therapies such as CAR-T cell therapy alongside established medications and multidisciplinary care. Individuals can now access a range of clinically recognized options, and UAE clinics have implemented the region’s first documented CAR-T therapy for treatment-resistant lupus.

Recent Developments in Lupus Treatment: CAR-T Cell Therapy in the UAE

A significant development in 2025 for lupus care is the clinical availability of Chimeric Antigen Receptor T-cell (CAR-T) therapy for patients with severe, treatment-resistant lupus in the UAE. Conducted by the Abu Dhabi Stem Cells Centre (ADSCC) and Yas Clinic, this approach may be considered for those who have not achieved disease control with existing therapies.

Overview of CAR-T Therapy for Lupus

• Mechanism: CAR-T therapy involves extracting a patient’s T-cells, modifying them in specialized laboratories to target specific B cells, and re-infusing them intravenously.
• Purpose: The treatment aims to address autoimmune processes, providing an opportunity for improved immune regulation.
• Supporting Evidence: Initial clinical trials and the reported case at ADSCC suggest the potential for extended symptom-free periods. Results may vary, and ongoing clinical evaluation is standard.
• Eligibility: Typically considered for individuals with lupus that remains active despite standard therapies, based on detailed evaluation by a specialist medical team.
• Procedure Timeline: The process generally takes about five weeks, including patient screening, cell extraction, modification, and monitored administration.
• Cost Considerations: Costs are determined based on individual circumstances and the specific care center. Some UAE insurance providers may partially cover therapy costs when other options have been explored.
• Access: Currently provided at specialized facilities such as ADSCC and Yas Clinic, which have the required laboratory capabilities for such cellular therapies.

Established Lupus Medications and Management Approaches

For most lupus patients, current treatments are based on well-supported and widely practiced medication protocols:

• Disease Modifying Anti-Rheumatic Drugs (DMARDs): The primary option for long-term disease management, aimed at reducing inflammation and minimizing organ involvement.
• Biologic Therapies: Utilized when additional immune modulation is warranted and other medications have been insufficient.
• Corticosteroids: Administered for acute exacerbations, with dosing and duration carefully considered due to side effect potential.
• Immunosuppressants: Employed for disease control, with patients monitored closely for adverse effects.
• Medications for Symptom Relief: Such as analgesics and anti-inflammatory agents, provided as needed for symptom management.

Note: Treatment is individualized by rheumatology specialists based on factors such as disease activity, organ involvement, and patient health status. Medication regimens are regularly reviewed and updated according to best practices and the latest clinical guidelines.

Multidisciplinary Approaches to Lupus Care

Comprehensive management in the UAE prioritizes a collaborative, patient-centered model:

• Tailored Care Plans: Treatments are designed to account for each patient’s specific medical history and preferences.
• Expert Teams: Rheumatologists collaborate with nephrologists, dermatologists, cardiologists, and other experts to address diverse lupus manifestations.
• Advanced Diagnostics: Contemporary imaging and laboratory assessments support timely diagnosis and treatment optimization.
• Patient Education: Clinics emphasize instruction on disease monitoring, self-management, and informed decision-making to enhance patient involvement.

Facilities such as the ADSCC Rheumatology Department and other established rheumatology centers deliver these services using recognized clinical standards and up-to-date resources.

Managing Flare-Ups: Practical Strategies

Managing lupus flare-ups involves prompt recognition and a structured response. Approaches in 2025 include:

• Continuous Monitoring: Regular follow-ups with a rheumatologist support early identification of potential complications.
• Adaptive Medication Plans: Adjustments to existing therapy—such as corticosteroid or biologics administration—are made in response to individual flare characteristics.
• Lifestyle Recommendations: Patients receive advice on stress management, adequate rest, and minimizing exposure to identified triggers.
• Advanced Treatments for Refractory Flares: In select cases where standard interventions prove insufficient, options like CAR-T therapy may be discussed, always following comprehensive evaluation.

Self-Management at Home: While detailed at-home protocols are not specified here, leading clinics recommend ongoing communication with healthcare providers and adherence to personalized care plans at the first sign of health changes.

Accessing Lupus Care and Finding Medical Expertise

The UAE provides access to a broad network of board-certified rheumatologists and internationally accredited facilities equipped for the diagnosis and long-term management of lupus.

• Abu Dhabi Stem Cells Centre (ADSCC): Located on Mahdar Qutouf Street, Rowdhat, Abu Dhabi, offering advanced therapies and multidisciplinary care.
• Yas Clinic: Noted for its FACT accreditation and capacity for complex cellular therapies.
• Rheumatology Clinics: Numerous options are available throughout Dubai and other emirates, facilitating both initial diagnosis and ongoing treatment.

Getting Started: Patients are encouraged to consult a rheumatology specialist to confirm diagnosis, explore advanced therapies as appropriate, and receive comprehensive treatment planning tailored to their needs.

Ongoing Progress in the UAE’s Lupus Care Landscape

As of 2025, UAE centers such as ADSCC are recognized for contributing to advances in autoimmune disease management. The availability of new therapies and multidisciplinary care frameworks positions the UAE among leaders in patient-focused lupus research and treatment.

Summary Points for 2025

• CAR-T therapy is emerging as a potential option for selected individuals with drug-resistant lupus and is available through accredited centers in the UAE.
• Most patients continue to benefit from established medication regimens and coordinated care provided by multidisciplinary medical teams.
• Implementing timely medical assessment, proactive monitoring, and individualized treatment strategies supports improved quality of life.
• Consulting with rheumatology specialists remains the primary step for determining suitable care pathways and considering advanced therapies as appropriate.

Sources

• Abu Dhabi Stem Cells Centre Rheumatology Department
• Khaleej Times: UAE Lupus Treated at ADSCC Using CAR-T Cell Therapy
• Medarabia: List of Rheumatologists in Dubai (2025)

Disclaimer: All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. The information and materials contained in these pages and the terms, conditions and descriptions that appear, are subject to change without notice.